SignatureFD’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,361
| Closed | -$98.2K | – | 3571 |
|
|
2025
Q4 | $98.2K | Sell |
1,361
-149
| -10% | -$9.63K | ﹤0.01% | 1330 |
|
|
2025
Q3 | $65.8K | Buy |
1,510
+8
| +0.5% | +$323 | ﹤0.01% | 1499 |
|
|
2025
Q2 | $42.7K | Sell |
1,502
-77
| -5% | -$2.29K | ﹤0.01% | 1669 |
|
|
2025
Q1 | $46.6K | Buy |
1,579
+72
| +5% | +$2.24K | ﹤0.01% | 1609 |
|
|
2024
Q4 | $43.8K | Sell |
1,507
-86
| -5% | -$3.59K | ﹤0.01% | 1655 |
|
|
2024
Q3 | $73.2K | Buy |
1,593
+17
| +1% | +$738 | ﹤0.01% | 1385 |
|
|
2024
Q2 | $64.4K | Buy |
1,576
+29
| +2% | +$832 | ﹤0.01% | 1389 |
|
|
2024
Q1 | $39.5K | Buy |
1,547
+78
| +5% | +$1.22K | ﹤0.01% | 1665 |
|
|
2023
Q4 | $13.3K | Sell |
1,469
-277
| -16% | -$1.85K | ﹤0.01% | 2128 |
|
|
2023
Q3 | $11.1K | Buy |
1,746
+1,533
| +720% | +$13.2K | ﹤0.01% | 2150 |
|
|
2023
Q2 | $2.36K | Buy |
213
+180
| +545% | +$2.26K | ﹤0.01% | 2756 |
|
|
2023
Q1 | $507 | Hold |
33
| – | – | ﹤0.01% | 3096 |
|
|
2022
Q4 | $732 | Sell |
33
-107
| -76% | -$1.59K | ﹤0.01% | 3036 |
|
|
2022
Q3 | $2K | Buy |
+140
| New | +$2.68K | ﹤0.01% | 2835 |
|
|
2022
Q1 | – | Sell |
-25
| Closed | -$1K | – | 3298 |
|
|
2021
Q4 | $1K | Hold |
25
| – | – | ﹤0.01% | 2981 |
|
|
2021
Q3 | $1K | Buy |
+25
| New | +$543 | ﹤0.01% | 2902 |
|
Other funds holding RNAM
SignatureFD's RNAM Position: Q1 2026 in Review
SignatureFD sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 1,361 shares — an estimated $98.2K sold.
SignatureFD first reported a position in RNAM in Q3 2021 and held it in 16 quarters. The position peaked at $98.2K in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- SignatureFD reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- SignatureFD sold 1,361 Avidity Biosciences shares in Q1 2026, an estimated $98.2K.
- SignatureFD first reported a position in Avidity Biosciences in Q3 2021 and held it in 16 quarters.
- SignatureFD's Avidity Biosciences position peaked at $98.2K in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.